As the world becomes increasingly uncertain, bluebird bio Inc. (BLUE) offers stability

bluebird bio Inc. (NASDAQ: BLUE) closed the day trading at $6.53 up 5.49% from the previous closing price of $6.19. In other words, the price has increased by $+0.34 from its previous closing price. On the day, 4485393 shares were traded. BLUE stock price reached its highest trading level at $6.60 during the session, while it also had its lowest trading level at $6.16.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



For a better understanding of BLUE, let’s look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On August 02, 2022, Raymond James Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $8.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 11 when Leschly Nick sold 4,290 shares for $7.80 per share. The transaction valued at 33,480 led to the insider holds 280,149 shares of the business.

Colvin Richard A sold 557 shares of BLUE for $4,347 on Jan 11. The Chief Medical Officer now owns 74,231 shares after completing the transaction at $7.80 per share. On Jan 11, another insider, Obenshain Andrew, who serves as the President and CEO of the company, sold 3,178 shares for $7.80 each. As a result, the insider received 24,802 and left with 242,690 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 101.36 while its Price-to-Book (P/B) ratio in mrq is 3.35.

Stock Price History:

Over the past 52 weeks, BLUE has reached a high of $8.58, while it has fallen to a 52-week low of $2.87. The 50-Day Moving Average of the stock is 7.40, while the 200-Day Moving Average is calculated to be 5.66.

Shares Statistics:

Over the past 3-months, BLUE traded about 3.81M shares per day on average, while over the past 10 days, BLUE traded about 5.75M shares per day. A total of 102.92M shares are outstanding, with a floating share count of 101.97M. Insiders hold about 1.20% of the company’s shares, while institutions hold 81.30% stake in the company. Shares short for BLUE as of Oct 13, 2022 were 22.44M with a Short Ratio of 18.24M, compared to 20.1M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 29.10% and a Short% of Float of 39.90%.

Earnings Estimates

Current recommendations for the stock of the company come from 10 analysts. On average, analysts expect EPS of -$1.12 for the current quarter, with a high estimate of -$0.88 and a low estimate of -$1.3, while EPS last year was -$3.16. The consensus estimate for the next quarter is -$0.45, with high estimates of $1.27 and low estimates of -$1.13.

Analysts are recommending an EPS of between -$1.89 and -$5.25 for the fiscal current year, implying an average EPS of -$4.25. EPS for the following year is -$2.21, with 10 analysts recommending between -$0.98 and -$3.16.

Revenue Estimates

A total of 8 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $104.6M, while the lowest revenue estimate was $3.46M, resulting in an average revenue estimate of $18.04M. In the same quarter a year ago, actual revenue was $3.66M, up 392.60% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $69.56M in the next fiscal year. The high estimate is $128.55M and the low estimate is $16.3M. The average revenue growth estimate for next year is up 285.60% from the average revenue estimate for this year.